Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285530 | 0.86 | BTK (0.35) | JAK2JAK3JAK1BTK | |
| SCHEMBL18285529 | 0.86 | BTK (0.35) | JAK2JAK3JAK1BTK | |
| SCHEMBL28490359 | 0.86 | BTK (0.35) | JAK2JAK3JAK1BTK | |
| SCHEMBL18285525 | 0.86 | BTK (0.35) | JAK2JAK3JAK1BTK | |
| SCHEMBL18285718 | 0.82 | HCAR1 (0.41) | JAK2JAK1BTK | |
| SCHEMBL30111817 | 0.82 | HCAR1 (0.41) | JAK2JAK1BTK | |
| SCHEMBL18289981 | 0.82 | HCAR1 (0.41) | JAK2JAK1BTK | |
| SCHEMBL18818280 | 0.82 | HCAR1 (0.41) | JAK2JAK1BTK | |
| SCHEMBL18818279 | 0.82 | HCAR1 (0.41) | JAK2JAK1BTK | |
| SCHEMBL22902683 | 0.72 | JAK1 (0.38) | JAK2JAK3JAK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | JAK2 6/4885JAK3 19/4885JAK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.